Product Details
Glenmark Pharmaceuticals Inc., USA launched Sugammadex Injection in two dosage strengths: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION® Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
Market Context
According to IQVIA® sales data for the 12-month period ending May 2026, the BRIDION® Injection, 100 mg/mL market achieved annual sales of approximately $1.6 billion. This market data includes both the brand and all available therapeutic equivalents.
Strategic Significance
Marc Kikuchi, President & Business Head, North America, commented that this launch represents a significant addition to Glenmark's growing U.S. injectables portfolio and strengthens the company's presence in the hospital and institutional segment. He noted that achieving a Day 1 launch reflects the agility, preparedness and execution discipline behind Glenmark's injectable strategy.
Important Qualifications
Glenmark's Sugammadex Injection is only approved for the indication(s) listed in Glenmark's approved label, which may be different than the approved RLD indications. All brand names and trademarks are acknowledged as property of their respective owners.
Company Background
Glenmark Pharmaceuticals Ltd. is identified as a global, research-led pharmaceutical company with 11 world-class manufacturing facilities across four continents, supported by six R&D centres, and a commercial footprint in 80+ countries. The company focuses on respiratory, dermatology, and oncology therapeutic areas.